Literature DB >> 24223639

Computational pharmacological comparison of Salvia miltiorrhiza and Panax notoginseng used in the therapy of cardiovascular diseases.

Chun-Song Zheng1, Xiao-Jie Xu, Hong-Zhi Ye, Guang-Wen Wu, Hui-Feng Xu, Xi-Hai Li, Su-Ping Huang, Xian-Xiang Liu.   

Abstract

The herb pair comprising Salvia miltiorrhiza (SM) and Panax notoginseng (PN) has been used as a classical formula for cardiovascular diseases (CVDs) in China and in western countries. However, the pharmacology of SM and PN in this herb pair has not been fully elucidated. The aim of this study was to compare the mechanisms of SM and PN at the molecular level for the treatment of CVDs. We used a systems pharmacology approach, integrating ligand clustering, chemical space, docking simulation and network analysis, to investigate these two herbal medicines. The compounds in SM were attached to clusters 2, 3, 5, 6, 8 and 9, while the compounds in PN were attached to clusters 1, 2, 4, 5, 6, 7, 8 and 10. The distributions of chemical space between the compounds from SM and PN were discrete, with the existence of small portions of overlap, and the majority of the compounds did not violate 'Lipinski's rule of five'. Docking indicated that the average number of targets correlated with each compound in SM and PN were 5.0 and 3.6, respectively. The minority nodes in the SM and PN drug-target networks possessed common values of betweenness centrality, closeness centrality, topological coefficients and shortest path length. Furthermore, network analyses revealed that SM and PN exerted different modes of action between compounds and targets. These results suggest that the method of computational pharmacology is able to intuitively trace out the similarities and differences of two herbs and their interaction with targets from the molecular level, and that the combination of two herbs may extend their activities in different potential multidrug combination therapies for CVDs.

Entities:  

Keywords:  Panax notoginseng; Salvia miltiorrhiza; cardiovascular disease; computational pharmacology

Year:  2013        PMID: 24223639      PMCID: PMC3820668          DOI: 10.3892/etm.2013.1291

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


Introduction

Cardiovascular diseases (CVDs) are the leading cause of death globally. Based on data from the World Health Organization (WHO), an estimated 17.3 million people died from CVDs in 2008, representing 30% of all global deaths (1). To date, the majority of patients with CVDs have been treated with drug therapies. The main drugs on the market are diuretics, vasodilators, anticoagulants, antiplatelet agents and β-blockers. While these drugs have yielded desired responses, they have also led to unwanted side-effects (2,3). Multiherb therapy, as an essential component of traditional medicine systems, has been utilized for thousands of years in China and other countries. It has exhibited improved curative efficacies and fewer side-effects, and has been used in the prevention of disease (4). It has been revealed that the majority of herbal medicines exhibit multiple cardiovascular effects (5). Thus, multiherb therapy may be one of the best conventional and complementary medical approaches in the prevention and treatment of CVDs. Salvia miltiorrhiza (SM) and Panax notoginseng (PN) have been widely used in combination in Traditional Chinese Medicine (TCM) for the therapy of CVDs in China and other countries, including the United States (6–8). It has been demonstrated that these two herbs are compatible and have a synergistic effect (7). However, the molecular mechanisms underlying their compatibility have yet to be clearly elucidated. Numerous computational pharmacological studies, which have been generated using library analysis, quantitative structure-activity relationship (QSAR), receptor-ligand interaction and biological networks, have been developed to clarify the pharmacology and efficacy of TCM (9,10). Therefore, in the present study, we compared the computational pharmacology of SM and PN at the molecular level, in order to enhance the understanding of factors affecting compatibility in TCM and to accelerate modern TCM development.

Materials and methods

Preparation of SM and PN chemical databases

The structures identified in the medicinal herbs of SM and PN were taken from the Chinese Herbal Drug Database and the Handbook of the Constituents in Chinese Herb Original Plants (11,12). The total number of compounds in SM and PN was 53 and 57, respectively. These compounds were converted into three-dimensional structures and energy optimizations were performed using the Discovery Studio 2.0 (DS 2.0) software (Accelrys Inc., San Diego, CA, USA), based on the Merck Molecular Force Field (MMFF). Following this, the protocol of Cluster Ligands was used to cluster the compounds from the SM and PN chemical databases (13).

Calculation of molecular descriptors

The protocol from ‘Calculate Molecular Properties’ in the QSAR module of DS 2.0 was employed to calculate the descriptors for the compounds from the SM and PN chemical databases. The chemical space was constructed using 150 diversity descriptors, including the molecular properties of one, two and three dimensions (14,15). Principal component analysis (PCA) was then performed to map the distribution of the compounds in chemical space.

Molecular docking

The modern docking program LigandFit, within DS 2.0, was used to perform the molecular docking. The crystal structures of 16 key proteins associated with CVDs (16,17) were downloaded from the Research Collaboratory for Structural Bioinformatics (RCSB) protein data bank (PDB; Table I; www.rcsb.org). All crystallographic water was removed from the file and hydrogen atoms were added. The inhibitor from the PDB file was used to define the active site. The compounds from the SM and PN chemical databases were docked into the protein models. All docked structures were sorted according to their DockScore. The compounds with the top-five DockScores were selected as potential active compounds, as described previously (18).
Table I.

Sixteen proteins associated with CVDs.

ProteinPDB codeProteinPDB code
TNF-α2AZ5Factor IXa1X7A
eNOS1M9JFactor Xa1FJS
COX-11CQEFactor VIIa1YGC
COX-26COXFactor XI1ZSL
PPARγ2HFPHMG-CoA1HW8
HO-13TGMACE I1UZE
Thrombin1YPJACE II1R4L
ER1X7JRenin1BIL

CVDs, cardiovascular diseases; PDB, protein data bank; TNF-α, tumor necrosis factor-α; eNOS, endothelial nitric oxide synthase; COX, cyclooxygenase; PPARγ, peroxisome proliferator activated receptor γ; HO, heme oxygenase; ER, estrogen receptor; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; ACE, angiotensin-converting enzyme.

Network construction and analysis

Cytoscape 2.8.3 was used for network construction (19). The potential active compounds and their corresponding target proteins were connected to each other to generate a drug-target (D-T) network. In this network, the nodes represented compounds or proteins and the edges represented the compound-target interactions. All data were analyzed using Cytoscape plugins.

Results

Comparison of the SM and PN chemical databases: Clustering distribution

The compounds from the SM and PN chemical databases were clustered by employing the default settings of Cluster Ligands (Fig. 1). Fig. 1 shows that the compounds in SM were attached to six clusters, known as clusters 2, 3, 5, 6, 8 and 9, while the compounds in PN were attached to eight clusters, known as clusters 1, 2, 4, 5, 6, 7, 8 and 10. These results indicate that SM and PN have similarities and differences with regard to chemical structure clustering.
Figure 1.

Clustering distribution of compounds from the chemical databases of Salvia miltiorrhiza (SM) and Panax notoginseng (PN).

Comparison of the SM and PN chemical databases: Chemical space

Diversity descriptors (n=150) were used to map the chemical space of the SM and PN chemical databases using PCA (Fig. 2). A number of the key molecular descriptors of the compounds from the two databases are shown in Table II. The results were as follows: i) Considerable dispersion was observed in the first three principal components; ii) there was only a small overlap between the databases of the two molecules in chemical space; iii) the majority of the molecules did not violate ‘Lipinski’s rule of five’ (20).
Figure 2.

Principal component analysis of compounds from the chemical databases of Salvia miltiorrhiza (SM) and Panax notoginseng (PN). The black and white circles represent the former and the latter, respectively. PC1, first principal component; PC2, second principal component; PC3, third principal component.

Table II.

Maximum, minimum and mean of the molecular descriptors of the SM and PN chemical databases.

DescriptorsSM
PN
MaximumMinimumMeanMaximumMinimumMean
Molecular weight718.61154.12326.401271.44118.18355.78
No. of hydrogen acceptors1614.082804.04
No. of hydrogen donors901.701802.49
AlogP8.080.613.5710.41−4.544.34
No. of rotatable bonds1401.981907.96
Molecular volume438.3588.49219.33853.7286.43270.14
Molecular surface area652.14148.91313.641221.90128.43378.57
Molecular polar surface area278.0320.2375.31456.44067.57

SM, Salvia miltiorrhiza; PM, Panax notoginseng.

Comparison of the SM and PN chemical databases: Compounds with potential biological activity

To investigate whether the compounds in SM and PN were likely to be active in CVDs, the compounds with potential biological activity were predicted using virtual docking. The docking showed that various bioactive compounds in SM and PN targeted multiple proteins associated with CVDs. The average number of targets correlated with each compound in SM and PN were 5.0 and 3.6, respectively.

Comparison of the SM and PN chemical databases: D-T network

The D-T network was generated by connecting the potential active compounds to their CVD-associated targets, in order to further clarify the associations between the potentially active compounds and their targets (Figs. 3 and 4). The simple parameters of the networks for SM and PN are shown in Table III. Plot parameters of these networks were used to characterize the global map of D-T interactions (Fig. 5) and the degree of compound nodes in the network was analyzed (Fig. 6). The key compounds with the top-five degrees in the two networks are shown in Table IV. These results demonstrated that SM and PN are able to act on multiple targets and exhibit different modes of action between compounds and targets.
Figure 3.

Salvia miltiorrhiza (SM) drug-target network. The white and pink circles represent target proteins associated with cardiovascular diseases (CVDs) and SM compounds, respectively.

Figure 4.

Panax notoginseng (PN) drug-target network. The white and pink represent target proteins associated with cardiovascular diseases (CVDs) and PN compounds, respectively.

Table III.

Network properties of the SM and PN D-T networks.

ParametersSM D-T networkPN D-T network
Network density0.1610.114
Network heterogeneity0.5960.652
Network centralization0.2750.308
Characteristic path length3.5442.762
Average no. of neighbors5.0004.211
Shortest paths992 (100%)1,406 (100%)

SM, Salvia miltiorrhiza; D-T, drug-target; PN, Panax notoginseng.

Figure 5.

(A–D) Network analyses of Salvia miltiorrhiza (SM) and Panax notoginseng (PN) drug-target (D-T) networks. Parameter statistics of the SM D-T network are shown in black and the parameter statistics of the PN D-T network are shown in white.

Figure 6.

Distribution of the number of targets associated with each compound in Salvia miltiorrhiza (SM) and Panax notoginseng (PN).

Table IV.

Key compounds with the top-five degrees in the SM D-T network and PN D-T network.

SM D-T network
PN D-T network
IndexChemical nameDegreeIndexChemical nameDegree
SM29Monomethyl lithospermate13PN50Quercetin15
SM40Salvianolic acid C13PN10Dicapryl phthalate9
SM39Salvianolic acid A12PN11Diisocapryl phthalate8
SM23Methyl rosmarinate8PN53Stigmasterol7
SM1Baicalin7PN47Panaxynol6

SM, Salvia miltiorrhiza; D-T, drug-target; PN, Panax notoginseng.

Discussion

CVDs are the leading cause of mortality in the world and pose a serious threat to human health. The diseases are complex and multifactorial and are caused by environmental, genetic and clinical risk factors (21). Therefore, CVDs tend to result from multiple molecular abnormalities. As a result, one drug acting on a single target may not lead to the effective treatment of the CVDs (22,23), and drug therapies addressing multiple targets have been receiving increasing focus. For many years, numerous preparations of the herb pair comprising SM and PN have been used in the treatment of patients with CVDs (24). In the current study, a number of compounds in SM and PN, distributed among the different class groups, are shown in Fig. 1. The results reflect the structural diversity in the molecular composition of SM and PN and the differences between them. SM and PN were shown to possess a broad and different diversity in chemical space (Fig. 2), which indicates that they are likely to exert different effects (15). The statistics of the drug-like properties of the compounds from the SM and PN chemical databases (Table II) revealed the mean molecular weights to be 326.40 and 355.78, respectively; the mean number of hydrogen bond acceptors was 4.08 and 4.04, respectively; the mean number of hydrogen bond donors was 1.70 and 2.49, respectively and the mean AlogP was 3.57 and 4.34, respectively. According to the ‘rule of five’ (20), these compounds have desirable drug-like properties that make them suitable for use as oral drugs in humans. These results provided a good foundation for the screening of suitable active compounds. A docking screening protocol was used to identify the compounds with multitarget potential for targets associated with CVDs using LigandFit. The docking results showed that the compounds in SM and PN exhibited potential biological activity with one or more target proteins. Among these compounds, 81.25% of the compounds in SM and 59.05% of the compounds in PN were able to act on more than one target protein. To further compare the effects of SM and PN on CVDs, we used the screening compounds and their interaction targets to generate a bipartite graph of drug-target interactions, in which a compound and a protein were connected to each other if the protein was an action target of the compound, giving rise to SM (Fig. 3) and PN (Fig. 4) D-T networks. The analyses of these networks (Fig. 5) showed minority common values of betweenness centrality, closeness centrality, topological coefficients and shortest path length, in addition to discriminating the detailed actions of SM and PN on CVDs. Zhu et al (25) proposed that identifying the common behavioral features from the network was likely to provide important information to enable the understanding of the drug-target interaction mechanisms in the human body; therefore, the topological analysis may reflect global knowledge concerning the particular properties of compounds and proteins involved in the network. The results indicated that SM and PN exhibited different modes of action. In addition, the compounds in SM and PN possessed different degrees in the model of the D-T network (Fig. 6 and Table IV). The majority of the compounds in Table IV have been described in previous studies (26–29). As mentioned previously, the herb pair consisting of SM and PN may possess a range of functions in the treatment of CVDs, via different compounds combining with different targets. Furthermore, the different modes of action of the pair may result in SM and PN exerting synergistic effects in CVDs. Zheng et al (7) demonstrated that SM primarily acted to expand blood vessels, while PN mainly participated in the protection of cardiac myocytes. Therefore, the combination of these two herbs improves coronary circulation and reduces the symptoms of myocardial ischemia. This may further corroborate the proposal that SM and PN are able to treat CVDs via different modes of action and that the combination of the two herbs is able to enhance the therapeutic effects. In conclusion, the results of the present study demonstrated that: i) The compounds in SM and PN have diverse and drug-like properties; ii) the compounds in SM and PN have multitarget potential for targets associated with CVDs, and iii) the combination of SM and PN may enhance their activities in different potential multidrug combination therapies for CVDs. Furthermore, the method of computational pharmacology is able to intuitively trace out the different details of the structural classification, chemical space and modes of action of the compounds in SM and PN. This may be used as a new method for the identification of SM and PN, and to enable the improved understanding of herb pairs at the molecular level.
  17 in total

1.  A 3D structure database of components from Chinese traditional medicinal herbs.

Authors:  Xuebin Qiao; Tingjun Hou; Wei Zhang; SenLi Guo; Xiaojie Xu
Journal:  J Chem Inf Comput Sci       Date:  2002 May-Jun

Review 2.  Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future?

Authors:  Marie Therese Cooney; Alexandra Dudina; Ralph D'Agostino; Ian M Graham
Journal:  Circulation       Date:  2010-07-20       Impact factor: 29.690

3.  Chemical space and biology.

Authors:  Christopher M Dobson
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

4.  The analysis of the drug-targets based on the topological properties in the human protein-protein interaction network.

Authors:  Mingzhu Zhu; Lei Gao; Xia Li; Zhicheng Liu; Chun Xu; Yuqing Yan; Erin Walker; Wei Jiang; Bin Su; Xiujie Chen; Hui Lin
Journal:  J Drug Target       Date:  2009-08       Impact factor: 5.121

5.  Optimization and visualization of molecular diversity of combinatorial libraries.

Authors:  M Hassan; J P Bielawski; J C Hempel; M Waldman
Journal:  Mol Divers       Date:  1996-10       Impact factor: 2.943

6.  Computational approaches for exploring the potential synergy and polypharmacology of Duhuo Jisheng Decoction in the therapy of osteoarthritis.

Authors:  Chun-Song Zheng; Xiao-Jie Xu; Hong-Zhi Ye; Guang-Wen Wu; Xi-Hai Li; Su-Ping Huang; Xian-Xiang Liu
Journal:  Mol Med Rep       Date:  2013-04-03       Impact factor: 2.952

7.  The effect of Compound Danshen Dripping Pills, a Chinese herb medicine, on the pharmacokinetics and pharmacodynamics of warfarin in rats.

Authors:  Yang Chu; Ling Zhang; Xiang-yang Wang; Jia-hua Guo; Zhi-xin Guo; Xiao-hui Ma
Journal:  J Ethnopharmacol       Date:  2011-08-29       Impact factor: 4.360

8.  The multi-target capabilities of the compounds in a TCM used to treat sepsis and their in silico pharmacology.

Authors:  Shitang Ma; Chengtao Feng; Xiaolin Zhang; Guoliang Dai; Changyin Li; Xiaogui Cheng; Peixun Liu; Wenzheng Ju; Hao Yu
Journal:  Complement Ther Med       Date:  2013-01-05       Impact factor: 2.446

9.  Cytoscape 2.8: new features for data integration and network visualization.

Authors:  Michael E Smoot; Keiichiro Ono; Johannes Ruscheinski; Peng-Liang Wang; Trey Ideker
Journal:  Bioinformatics       Date:  2010-12-12       Impact factor: 6.937

Review 10.  Salvianolic acids: small compounds with multiple mechanisms for cardiovascular protection.

Authors:  Jennifer Hui-Chun Ho; Chuang-Ye Hong
Journal:  J Biomed Sci       Date:  2011-05-11       Impact factor: 8.410

View more
  9 in total

Review 1.  Network Pharmacology Approach for Medicinal Plants: Review and Assessment.

Authors:  Fatima Noor; Muhammad Tahir Ul Qamar; Usman Ali Ashfaq; Aqel Albutti; Ameen S S Alwashmi; Mohammad Abdullah Aljasir
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-04

2.  Protocatechuic aldehyde inhibits TNF-α-induced fibronectin expression in human umbilical vein endothelial cells via a c-Jun N-terminal kinase dependent pathway.

Authors:  Yue-Feng Tong; Yong Liu; Zhi-Xing Hu; Zhe-Cheng Li; Agula A
Journal:  Exp Ther Med       Date:  2015-11-25       Impact factor: 2.447

3.  Protective effects of Salvia miltiorrhiza injection against learning and memory impairments in streptozotocin-induced diabetic rats.

Authors:  Huabo Cai; Luya Lian; Yu Wang; Yuanyuan Yu; Wei Liu
Journal:  Exp Ther Med       Date:  2014-08-19       Impact factor: 2.447

4.  Comparative effectiveness of Di'ao Xin Xue Kang capsule and Compound Danshen tablet in patients with symptomatic chronic stable angina.

Authors:  Yanan Yu; Siyuan Hu; Guoxin Li; Jie Xue; Zhuoming Li; Xiangling Liu; Xiyan Yang; Bo Dong; Donghai Wang; Xiaofeng Wang; Shurong Liu; Jun Liu; Bingwei Chen; Liying Wang; Songshan Liu; Qiguang Chen; Chunti Shen; Zhong Wang; Yongyan Wang
Journal:  Sci Rep       Date:  2014-11-14       Impact factor: 4.379

5.  Systems pharmacology exploration of botanic drug pairs reveals the mechanism for treating different diseases.

Authors:  Wei Zhou; Jinan Wang; Ziyin Wu; Chao Huang; Aiping Lu; Yonghua Wang
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

6.  Cardioprotective effects of traditional Chinese medicine Guanmaitong on acute myocardial infarction.

Authors:  Xing-Hua Wang; Guang-Ping Li; Wan-Song Yang; Zhan-Quan Jiao; Hong-Mei Liu; Yan-Ping Ni
Journal:  Exp Ther Med       Date:  2016-11-08       Impact factor: 2.447

7.  Integration of traditional Chinese medicine and nibble debridement and dressing method reduces thrombosis and inflammatory response in the treatment of thromboangiitis obliterans.

Authors:  Jianhua Li; Jingfeng Zhong; Chunfa Huang; Jiewen Guo; Bingyu Wang
Journal:  Ann Transl Med       Date:  2021-09

8.  Notoginsenoside R1 increases neuronal excitability and ameliorates synaptic and memory dysfunction following amyloid elevation.

Authors:  Shijun Yan; Zhi Li; Hang Li; Ottavio Arancio; Wensheng Zhang
Journal:  Sci Rep       Date:  2014-09-12       Impact factor: 4.379

Review 9.  Synergism of Chinese Herbal Medicine: Illustrated by Danshen Compound.

Authors:  Xuefeng Su; Zhuoting Yao; Shengting Li; He Sun
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-13       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.